At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 248 target
Drug / intervention
HS-10386drug
Likely dose
HS-10386 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05911464Phase 1RecruitingUpdate OverdueUpdated 36mo ago · Completion was 8mo agoEnrollment Stalled
Long Recruiting
Update Overdue
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10386 in Participants With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating HS-10386 for Advanced Solid Tumor. Currently recruiting, targeting 248 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
2024202520262027
Enrollment StartMar 2023
First PostedJun 2023
Primary CompletionOct 2025
TodayJul 2026
Study CompletionOct 2027
First PostedJun 22, 2023
Enrollment StartMar 2, 2023
Primary CompletionOct 31, 2025
Study CompletionOct 31, 2027
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 3.0 years ago
Interventions
HS-10386drug
Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined